Insulin Drugs Market Definition

The insulin drugs market consists of manufacturers’ sales of insulin drugs and types of Insulin by entities (organizations, sole traders and partnerships) which are used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amount of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. Insulin is available as synthetic human insulin that is laboratory grown to mimic the human insulin) and insulin analogues that are genetically modified human insulin. Insulin is most commonly administered subcutaneously.

Injectable Drug Delivery Devices Market Definition

The injectable drug delivery devices market consists of sales of injectable drug delivery devices and related products such as conventional syringes, needle-free injectors, auto injectors and pen injectors by entities (organizations, sole traders, and partnerships). The market includes the sales of the injectable devices that have been extensively utilized for various routes of drug administration, such as intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular and others to treat medical conditions ranging from cancer, diabetes to autoimmune disorders.

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global therapeutic proteins market grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The therapeutic proteins market is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic protein drugs developed using protein engineering technologies and approved by the FDA in the past five years. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic protein market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic protein drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global therapeutic protein market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics

Diabetes Care Devices Market Definition

The diabetes care devices (or) equipment market consists of sales of diabetes care devices and related services by entities (organizations, sole traders and partnerships) that produce diabetes care devices used to monitor and control blood glucose levels in diabetic patients. This industry includes establishments that produce blood glucose test strips, continuous glucose monitoring devices, and blood glucose meters used to check blood glucose levels; insulin pens, syringes, pumps and injectors used to inject insulin; and others. Diabetes care devices are designed to diagnose, monitor or manage type I and type II diabetes mellitus. Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar.

Insulin drugs refer to medications that used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amounts of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The main product types of insulin drugs are prandial insulins, basal insulins, premixed insulins, and other insulins. A meal is referred to as a prandial. Postprandial (from post prandium) refers to the time after a meal, whereas preprandial refers to the time before a meal. The drugs are classified into branded drugs and generic drugs that are distributed by hospital pharmacies, retail pharmacies, drug stores, and others. The various applications include type II diabetes, type I diabetes, gestational diabetes, and prediabetes. The insulin drugs market research report is one of a series of new reports from The Business Research Company that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global insulin drugs market size will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global insulin drugs market size is expected to grow to $53.41 billion in 2027 at a CAGR of 10.0%. Changing lifestyles are leading to a higher prevalence of diabetes. This is expected to drive the demand for diabetes drugs during the forecast period. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes. According to a study, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period. High costs and long payback periods for investment in new diabetes drugs negatively impacted the market during the forecast period. The costs for drug approval processes that include multiple phases of clinical trials and screening processes with regulatory bodies such as the US FDA are very high. According to a study published in the journal JAMA, the cost of bringing a new drug from its conception to shelves was about $2.8 billion in 2020. These high costs and uncertainty regarding return on investments for drug development limited the investments by pharmaceutical companies in the development of new diabetic drugs, thus limiting the growth of the market during the historic period. There is an increasing trend of mergers and acquisitions for new formulations in the Insulin market and companies are investing in the development of new medicines in the insulin drugs market. For example, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool. This resulted in the turning off of one of the genes which were responsible for causing diabetes. This effectively decreased beta cell death and increased insulin production in the pancreas. Insulin maker, Novo Nordisk has developed a diabetes pill and planned to launch it in India by February 2022. This pill belongs to a blockbuster class of drugs, glucagon-like peptide-1 (GLP-1s) that stimulate insulin production. The new drug is expected to generate about $5 billion in annual sales. In July 2021, Eli Lilly and Company, a US-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of human drugs, acquired Protomer Technologies Inc. for an amount of $1 billion. Through this acquisition, Lilly enhances its capabilities to make the lives of diabetes patients better, and we're still committed to offering practical solutions, such as advancements in insulin therapy. The development of glucose-sensing insulin, which has the potential to significantly enhance both the therapeutic efficacy and safety of insulin therapy, is the next step in diabetes care. Protomer Technologies Inc. is a US-based pre-clinical stage biotechnology company pioneering in research and technology development for the treatment of metabolic disorders. Major players in the insulin drugs market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog, Actrapid, Admelog, Novolin/Actrapid/Insulatard, Ryzodeg, Sanofi, Soliqua/Suliqua, Toujeo, Tresiba, and Xultophy. North America was the largest region in the insulin drugs market in 2022. The Middle East is expected to be the largest growing region in the global insulin drugs market during the forecast period. The regions covered in the global insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global insulin drugs market is segmented - 1) By Product Type: Prandial Insulins, Basal Insulins, Premixed Insulins, Other Insulins 2) By Application: Type II Diabetes, Type I Diabetes, Gestational Diabetes, Prediabetes 3) By Drug Classification: Branded Drugs, Generic Drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drugs Stores, Other Distribution Channels

Smart insulin pens are insulin delivery devices that keep track of the volume, time, and type of dosage. These devices may also perform tasks such as generating reports to be shared with healthcare professionals. The main types of smart insulin pens are first-generation pens and second-generation pens (Bluetooth enabled, USB connected). The second-generation smart insulin pens are devices that are engineered with Bluetooth or USB features to enable closer monitoring. The smart insulin pens are either prefilled or reusable that is used to treat type 1 diabetes and type 2 diabetes. The various end-users of smart insulin pens are hospitals and clinics, ambulatory surgical centres, and home care settings. The smart insulin pens market research report is one of a series of new reports from The Business Research Company that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart insulin pens market size will grow from $0.09 billion in 2022 to $0.10 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart insulin pens market size is expected to grow to $0.12 billion in 2027 at a CAGR of 6.2%. An accurate dose of insulin can be achieved than a vial or a syringe with an insulin pen. For kids who need to take insulin during school time and visually impaired diabetic patients, an accurate dose of insulin can even be pre-set over the dosage dial which helps inaccurate delivery of dose at the time of injection. Echo Plus by Novo Nordisk which is a pediatric-friendly insulin pen allows even half-unit dosing with a maximum of 30 units. HumaPen Luxura HD from Lilly allows the delivery of insulin in half-unit increments and NovoPen Junior - Insulin Pen by Novo Nordisk can deliver highly accurate doses of insulin and finely adjusts small doses even half-unit increments. The accurate adjustments and delivery of doses of insulin can avoid either over-dosing or low-dosing of the drug which is expected to increase the demand for smart insulin pens and drive the market growth. Diabetics may be prescribed two types of insulin for better control over blood glucose levels. They usually prefer pre-mixed insulin (combination) or a method in which the insulin doses could be mixed and once puncture is necessary to deliver the different types of insulin doses required. Multiple punctures for the insulin delivery can lead to poor adherence to the medication which in turn results in poor glycemic control. A study published states that poor glycemic control (A1c>7%) was reported in 68% of respondents and there was an association between A1c >7% and poor adherence levels. Dislike towards injection to a large extent and needle phobia can result in poor adherence levels. It is estimated that over 10% of the population has needle phobia. These factors can reduce the adherence of smart insulin pens where two types of insulin can't be mixed and result in multiple needle punctures which thereby affect the purpose of the insulin being administered which is expected to hinder the market growth. The next generation of smart insulin pens goes far beyond memory storage. They help in calculating personalized doses, track glucose continuously, and connect with apps of smartphones to visualize the data. In September 2020, Medtronic plc introduced InPen™ that is integrated with Guardian Connect™ CGM data to manage their diabetes. It is the only FDA_cleared smart insulin pen for people on multiple daily injections. This enhances the ease of usage of smart insulin pens which is expected to boost the market. In February 2020, Senseonics a US-based medical technology company that primarily focuses on the design, development, and commercialization of glucose monitoring products announced a partnership with Companion Medical. The partnership will benefit both companies by integrating Eversense® CGM System with the InPen™ smart system for accurate insulin delivery. Companion Medical is a US-based company that aims at achieving desirable diabetes outcomes and manufactured InPen™ which is the US first FDA-approved insulin pen. Major players in the smart insulin pens market are Companion Medical, Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co. Ltd., Emperra GmbH E-Health Technologies, Digital Medics Pvt Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Jiangsu Delfu medical device Co. Ltd., and Bigfoot Biomedical. North America was the largest region in the smart insulin pens market in 2022. Western Europe was the second largest region in the global smart insulin pens market. The regions covered in the global smart insulin pens market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart insulin pens market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart insulin pens market is segmented - 1) By Type: First Generation Pens, Second Generation Pens (Bluetooth Enabled, USB Connected) 2) By End User: Hospitals & Clinics, Ambulatory Surgical Centres, Home Care Settings 3) By Usability: Prefilled, Reusable 4) By Application: Type 1 Diabetes, Type 2 Diabetes

Implantable infusion pumps are drug delivery systems implanted in the patients body that pump the medication into the blood stream in a controlled manner. The implantable infusion pumps market is segmented by type into patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. The insulin pump is a small device that is put beneath the skin during the operation to deliver insulin in diabetic patients. The various applications of implantable infusion pumps are oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and others that are used by hospitals, ambulatory surgical centers, and specialty clinics. The implantable infusion pumps market research report is one of a series of new reports from The Business Research Company that provides implantable infusion pumps market statistics, including implantable infusion pumps industry global market size, regional shares, competitors with a implantable infusion pumps market share, detailed implantable infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the implantable infusion pumps industry. This implantable infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable infusion pumps market grew from $18.26 billion in 2022 to $19.14 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable infusion pumps market is expected to grow from $23.12 billion in 2027 at a CAGR of 4.8%. The increased prevalence of people with chronic pain, cancer, and diabetes is expected to drive the demand for implantable infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, as the aging population and shifts in social behavior lead to a gradual increase in these diseases. In diseases such as chronic arachnoiditis, which is a condition where one of the membranes surrounding the spinal cord swells, implantable infusion pumps deliver lower dosages of drugs and tend to provide more efficient pain relief. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the implantable infusion pumps market. The safety concern regarding implantable infusion pumps is a key factor hampering the growth of the implantable infusion pumps market. The magnetic resonance (MR) system can be useful in the diagnosis of a wide range of conditions and diseases, but the MRI setting poses a risk factor for patients with implantable infusion pumps. An MRI examination can influence the programming or functionality of an infusion pump, even if specific requirements have been met. The US food and drug administration received evidence of significant adverse effects including harm to the patient and death associated with the use of implantable infusion pumps in the MR field. Therefore, the safety concerns regarding implantable infusion pumps are expected to limit the growth of the implantable infusion pumps market. Companies in the implantable infusion pump market are increasingly focusing on developing smart infusion pumps. The use of wireless technology in health monitoring devices is increasing, which enhances the ease of usage, connectivity, and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results, which can be used for further study and to check the health condition of the individual. Software platforms are being developed that allow patient monitoring and reduce human error. In September 2021, Medtronic, a US-based medical device company, acquired implanted infusion pump technology from Alfred E. Mann Foundation. The acquisition is aimed to improve insulin delivery in people with type-1 diabetes. Alfred E. Mann Foundation is a US-based scientific research foundation developing implantable infusion pumps and other medical devices. Major players in the implantable infusion pumps market are Medtronic, Boston Scientific Corporation, Nevro Corporation, Cyberonics, Baxter, B=. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical, Terumo Corporation, and Neuropace. North America was the largest region in the implantable infusion pumps market in 2022. Asia-Pacific was the second-largest region in the global implantable infusion pumps market. The regions covered in the global implantable infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global implantable infusion pumps market is segmented - 1) By Type: Patient-Controlled Analgesia (PCA) Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps, Other Types 2) By Applications: Oncology, Pediatrics/Neonatology, Gastroenterology, Hematology, Diabetes, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Insulin pens, syringes, pumps, and injectors are used to administer insulin to diabetic patients to control blood glucose levels. These devices are reusable or disposable tools used to inject the desired dose of insulin into the blood of a diabetic patient. The main types of insulin pens, syringes, pumps, and injector devices and equipment are pens, injectors, pumps, and syringes. The syringe is a device used to inject fluids into or withdraw them from something. The pens used are both reusable and disposable. The pumps used are tube pumps and tubeless pumps. The various end-users are hospitals, home care, and others.d-users are hospitals, home care, and others. The insulin pens, syringes, pumps, and injectors devices and equipment market research report is one of a series of new reports from The Business Research Company that provides insulin pens, syringes, pumps, and injectors devices and equipment market statistics, including insulin pens, syringes, pumps, and injectors devices and equipment industry global market size, regional shares, competitors with a insulin pens, syringes, pumps, and injectors devices and equipment market share, detailed insulin pens, syringes, pumps, and injectors devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the insulin pens, syringes, pumps, and injectors devices and equipment industry. This insulin pens, syringes, pumps, and injectors devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global insulin pens, syringes, pumps and injectors market size will grow from $21.09 billion in 2022 to $22.81 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The insulin pens, syringes, pumps and injectors market size is expected to grow to $29.75 billion in 2027 at a CAGR of 6.9%. An increase in the prevalence of diabetes globally is driving the growth of the insulin pens, syringes, pumps, and injectors market. The increase in the number of people suffering from obesity, unhealthy eating habits, physical inactivity, and the increasing geriatric population are some of the key factors which are leading to the increase in the global prevalence of diabetes. According to the US Centers for Disease Control and Prevention (CDC) in 2020, around 34.2 million people in the U.S. were suffering from diabetes. Also, according to the International Diabetes Federation, in 2021, globally approximately537 million adults were living with diabetes; by 2045, this number would rise to 783 million, driving the insulin pens, syringes, pumps, and injectors market. Resistance towards self-injection by patients is restraining the insulin pens, syringes, pumps, and injectors market. The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake. According to a report by, National Center for Biotechnology Information (NCBI) anxiety about and the fear of injection-associated pain has been estimated to affect approximately 30%–50% of patients, before the initiation of diabetes education interventions. The report also stated that close to 28% of patients were unwilling to initiate insulin therapy, if prescribed because they were not confident about handling the injections and the anticipated needle pain due to self-injection. This resistance to self-injection due to the fear of needles is hampering the growth of the market. Many companies are focusing on technological advancements in insulin delivery systems to deliver insulin effectively and safely. For instance, in September 2022, the FDA approved the use of Omnipod 5 for children over 2 years with type 1 diabetes. Omnipod is the first tubeless automated insulin delivery aid for people with type 1 diabetes. The insulin pens, syringes, pumps, and injectors devices and equipment market is regulated by authorities such as the US FDA and European Medicines Agency. For instance, FDA's Title 21 of the Code of Federal Regulations (CFR) provides guidelines for proper labeling of medical devices such as food, drugs, cosmetics, and other medical devices, the manufacturers of these devices must comply and adhere. FDA also provides strict label warnings prohibiting the sharing of insulin injectable medicines, to avoid infections in patients which are caused by the sharing of these insulin devices. In 2020, Medtronic, an Irish medical device company agreed to acquire Companion Medical, a manufacturer of InPen, for an undisclosed amount. The connected insulin pen helps users to manage their diabetes by tracking insulin doses and active insulin. This acquisition is an ideal strategic fit for Medtronic, to further simplify diabetes management and improve outcomes by optimizing dosing decisions for a large number of people using multiple daily injections (MDI). Companion Medical was founded by people with diabetes that fuels their drive to create insulin technologies that enable users to live their lives with diabetes solutions that make sense. Major players in the insulin pens, syringes, pumps, and injectors devices and equipment market are Novo Nordisk A/S, Eli Lilly and Company, Medtronic PLC., Abbott, Insulet Corporation, Sanofi, Roche F. Hoffmann-La Roche Ltd., Becton, Animas Corporation, and Ypsomed Holding AG. North America was the largest region in the global insulin pens, syringes, pumps, and injectors devices and equipment market in 2022. Asia-Pacific was the second largest market in insulin pens, syringes, pumps, and injectors devices and equipment market. The regions covered in the global insulin pens, syringes, pumps, and injectors devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the insulin pens, syringes, pumps, and injectors devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The insulin pens, syringes, pumps, and injectors market consist of sales of reusable pens, disposable pens, tubed pumps, and tubeless pumps that are used for injecting insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global insulin pens, syringes, pumps and injectors market is segmented - 1) By Type: Pens, Injectors And Pumps, Syringes 2) By End Users: Hospitals, Homecare, Other End Users 3) By Pens: Reusable, Disposable 4) By Pumps: Tubed Pumps, Tubeless Pumps